SCHEMBL4725803

SCHEMBL4725803

CCCCCCCCOc1c(OC)cc(NC(C)CCCN2C(=O)c3ccccc3C2=O)c2nc(C(C)(C)C)cc(CC)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.38
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
MAOB P27338 4/20 0.35
MAOA P21397 3/20 0.35
CNR2 P34972 1/20 0.35
PABPC1 P11940 1/20 0.34
CASP7 P55210 1/20 0.34
CASP6 P55212 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NSD2 O96028 1/20 0.34
MAPT P10636 1/20 0.34
ESR1 P03372 1/20 0.34
PGR P06401 1/20 0.34
HTR1A P08908 1/20 0.34
DRD1 P21728 1/20 0.34
PTGS1 P23219 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5083258 0.99 IDO1 (0.38) IDO1HSP90AA1HSP90AB1MAOBMAOA
SCHEMBL5082859 0.84 MAOA (0.43) MAOBMAOAKDM4ENSD2MAPT
SCHEMBL4727950 0.83 MAOA (0.44) MAOBMAOAKDM4ENSD2MAPT
SCHEMBL10947401 0.82 MAOA (0.53) IDO1HSP90AA1HSP90AB1MAOBMAOA
SCHEMBL10946825 0.82 MAOA (0.53) IDO1HSP90AA1HSP90AB1MAOBMAOA
SCHEMBL10948467 0.82 MAOA (0.53) IDO1HSP90AA1HSP90AB1MAOBMAOA
SCHEMBL10944049 0.82 MAOA (0.54) IDO1HSP90AA1HSP90AB1MAOBMAOA
SCHEMBL10942299 0.81 HSP90AA1 (0.54) IDO1HSP90AA1HSP90AB1MAOBMAOA
SCHEMBL10941487 0.81 HSP90AA1 (0.54) IDO1HSP90AA1HSP90AB1MAOBMAOA
SCHEMBL10942340 0.81 HSP90AA1 (0.54) IDO1HSP90AA1HSP90AB1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021210-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-02-21 WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
EP-1606263-A1 RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS Council of Scientific and Industrial Research (IN) 2005-12-21 EP disclosed
WO-2004085402-A1 RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-10-07 WO disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 IDO1 636/4885HSP90AA1 3159/4885HSP90AB1 3066/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN IDO1 3809/4885HSP90AA1 358/4885HSP90AB1 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.